Loading
Life sciences · Journal article
Small · October 18, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
ABSTRACT Cancer drug resistance, a major cause of chemotherapy failure, arises from multiple interconnected barriers, including reduced intracellular drug accumulation, enhanced drug efflux, adaptive survival signaling, increased DNA repair, and redox or metabolic remodeling. To address these limitations, recent advances in programmable DNA nanostructures have provided new opportunities for constructing multifunctional nanotherapeutic platforms. This review examines how the structural characteristics of DNA nanostructures influence drug delivery, molecular regulation, and resistance modulation, and analyzes how different DNA nanoplatforms, including tetrahedral framework nucleic acids, DNA origami, DNA nanoflowers, spherical nucleic acids, and hybrid DNA assemblies, contribute to therapeutic regulation. It then highlights their applications in overcoming major resistance‐associated barriers, such as inefficient cellular uptake, drug efflux, apoptosis evasion, DNA repair activation, and biochemical adaptation. Finally, it discusses the challenges in DNA nanostructure‐based cancer therapy and proposes future directions for improving stability, intracellular delivery, tumor accumulation, immune safety, and scalable manufacturing. These advances suggest that DNA nanostructures may serve as next‐generation programmable nanomedicine platforms for multilevel intervention against cancer drug resistance.